Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Guardant Health's share price for the quarter that ended in Dec. 2023 was $27.05. Guardant Health's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 121.6 Mil. Therefore, Guardant Health's market cap for the quarter that ended in Dec. 2023 was $3,290.1 Mil.
Guardant Health's quarterly market cap
declined
from Jun. 2023 ($4,212.3 Mil) to Sep. 2023 ($3,493.0 Mil) and
declined
from Sep. 2023 ($3,493.0 Mil) to Dec. 2023 ($3,290.1 Mil).
Guardant Health's annual market cap
declined
from Dec. 2021 ($10,178.7 Mil) to Dec. 2022 ($2,791.2 Mil) but then
increased
from Dec. 2022 ($2,791.2 Mil) to Dec. 2023 ($3,290.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Guardant Health's Enterprise Value for Today is $2,486.3 Mil.
Guardant Health Market Cap Historical Data
The historical data trend for Guardant Health's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Guardant Health's Market Cap
For the Diagnostics & Research subindustry, Guardant Health's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Market Cap distribution charts can be found below:
* The bar in red indicates where Guardant Health's Market Cap falls into.
Guardant Health Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Guardant Health's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Guardant Health Market Cap Related Terms
Thank you for viewing the detailed overview of Guardant Health's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health (Guardant Health) Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 